Interpace Biosciences, Inc. (OTCMKTS:IDXG) Sees Significant Drop in Short Interest

Interpace Biosciences, Inc. (OTCMKTS:IDXG) was the target of a large drop in short interest in the month of August. As of August 14th, there was short interest totaling 91 shares, a drop of 80.7% from the July 30th total of 472 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 17,299 shares, the days-to-cover ratio is currently 0.0 days.

Interpace Biosciences Stock Performance

The company’s fifty day moving average price is $1.59 and its 200 day moving average price is $1.75. Interpace Biosciences has a 1-year low of $0.77 and a 1-year high of $2.40. The stock has a market cap of $6.42 million, a price-to-earnings ratio of 18.12 and a beta of 0.61.

Interpace Biosciences (OTCMKTS:IDXG) last released its quarterly earnings data on Monday, August 10th. The business services provider reported $0.01 EPS for the quarter. The company had revenue of $9.13 million for the quarter. Interpace Biosciences had a return on equity of 145.40% and a net margin of 67.64%.

About Interpace Biosciences

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.